Anti-endotoxin vaccines: back to the future (Q22305428)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Anti-endotoxin vaccines: back to the future	scientific article

Statements

scholarly article

0 references

6 references

20 June 2019

4 August 2019

2 November 2019

18 November 2019

19 November 2019

31 July 2020

Anti-endotoxin vaccines: back to the future (English)

0 references

1 reference

4 August 2019

1 reference

2 November 2019

1 reference

18 November 2019

1 reference

19 November 2019

2 references

based on heuristic

inferred from title

31 July 2020

author name string

Alan S Cross

1

author given names

Alan S

author last names

Cross

1 reference

PubMed publication ID

8 February 2023

language of work or name

0 references

publication date

1 January 2014

6 references

20 June 2019

4 August 2019

2 November 2019

18 November 2019

19 November 2019

31 July 2020

7 references

20 June 2019

4 August 2019

2 November 2019

18 November 2019

19 November 2019

31 July 2020

5

0 references

1

0 references

219-25

0 references

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

6 references

Europe PubMed Central

20 June 2019

Europe PubMed Central

4 August 2019

Europe PubMed Central

2 November 2019

Europe PubMed Central

18 November 2019

Europe PubMed Central

19 November 2019

Europe PubMed Central

31 July 2020

Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

19 March 2017

Antibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

19 March 2017

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

19 March 2017

A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

19 March 2017

Efficacy and safety of recombinant human activated protein C for severe sepsis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

7 April 2017

The future of antibiotics and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Developing vaccines in the era of genomics: a decade of reverse vaccinology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

NDM-1 — A Cause for Worldwide Concern

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Long-term acute care hospital utilization after critical illness.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

ACTIVE IMMUNITY PRODUCED BY SO CALLED BALANCED OR NEUTRAL MIXTURES OF DIPHTHERIA TOXIN AND ANTITOXIN.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Antibiotic-resistant bugs in the 21st century--a clinical super-challenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

A case for immunization against nosocomial infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

The survival of strains of enteric bacilli in the blood stream as related to their sensitivity to the bactericidal effect of serum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Serological characterization of anti-endotoxin serum directed against the conjugate of oligosaccharide core of Escherichia coli type R4 with tetanus toxoid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Identification of a Cross-reactive Epitope Widely Present in Lipopolysaccharide from Enterobacteria and Recognized by the Cross-protective Monoclonal Antibody WN1 222-5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Salmonella O antigens and virulence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Human Antiserum for Prevention of the Local Shwartzman Reaction and Death from Bacterial Lipopolysaccharides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Lipid A and Anti-Lipid A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

27 September 2017

O antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Serological characterisation of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to O and rough antigens against endotoxin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Sensitivity of serologically classified strains of escherichia coli of human origin to the serum bactericidal system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Immunization with R mutants of S. Minnesota. I. Protection against challenge with heterologous gram-negative bacilli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Antilipopolysaccharide improves survival in primates subjected to heat stroke

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

30 May 2018

Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

19 June 2018

Bacteremia due to gram-negative bacilli other than the Salmonella; a clinical and therapeutic study

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

The Changing Pattern of Life-Threatening Microbial Disease

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

"Nightmare" bacteria on the rise in US hospitals, long-term care facilities

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

Trends in Resistance to Carbapenems and Third-Generation Cephalosporins among Clinical Isolates of Klebsiella pneumoniae in the United States, 1999–2010

1 reference

https://api.crossref.org/works/10.4161%2FVIRU.25965

21 January 2018

Vital signs: carbapenem-resistant Enterobacteriaceae

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

29 November 2018

The biological activity of a liposomal complete core lipopolysaccharide vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3916378

29 November 2018

Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protection against lethality of E. coli endotoxin with "O" antiserum

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoprophylaxis against klebsiella and pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Occurrence of serious bacterial infections since introduction of antibacterial agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary Study on Treatment of Septic Shock Patients with Antilipopolysaccharide IgG from Blood Donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAMA patient page. Sepsis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety And Immunogenicity Of A Polyvalent Escherichia Coli Vaccine In Human Volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The lingering consequences of sepsis: a hidden public health disaster?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production and characterization of a human hyperimmune intravenous immunoglobulin against Pseudomonas aeruginosa and Klebsiella species

1 reference

https://pubmed.ncbi.nlm.nih.gov/23974910

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/VIRU.25965

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q22305428&oldid=1950969725"